Sun Pharmaceutical Industries, Inc., based in New Jersey, has recalled 9,840 bottles of Morphine Sulfate extended-release tablets due to “Failed Dissolution Specifications.” The company initiated a Class II nationwide recall in the US on February 6, 2025.
The USFDA also stated that Zydus Pharmaceuticals (USA) Inc is recalling a lot of Nelarabine Injection, a drug used to treat certain cancers. A total of 36,978 vials of Nelarabine Injection (250mg/50mL, 5mg/mL) are being recalled due to “Failed Impurities/Degradation Specifications.” In addition, Zydus is recalling another 1,893 vials of the drug in the same strength. The Class II recall was initiated on February 13, 2025.
A Class II recall is issued when the use of a violative product may lead to temporary or medically reversible adverse health effects, with a low probability of serious health consequences.
Also Read: INOXGFL Group plans to list INOX Clean Energy in FY26; aims to garner ₹5,000 crore from IPO
